

***Enterococcus faecium*, Strain U0317**

**Catalog No. NR-28982**

**For research use only. Not for human use.**

**Contributor:**

Willem van Schaik, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

**Manufacturer:**

BEI Resources

**Product Description:**

Bacteria Classification: *Enterococcaceae*, *Enterococcus*

Species: *Enterococcus faecium*

Strain: U0317

Original Source: *Enterococcus faecium* (*E. faecium*), strain U0317 is an infectious clinical isolate collected from a hospitalized patient suffering from a urinary tract infection in the Netherlands in 2005.<sup>1</sup>

Comments: *E. faecium*, strain U0317 contains point mutations in the *gyrA* gene that confer resistance to ampicillin, and in the *parC* and *pbp5* genes, which confer resistance to ciprofloxacin.<sup>1</sup> *E. faecium*, strain U0317 contains intact *esp*, *hyl* and *acm* virulence genes.<sup>1</sup> *E. faecium*, strain U0317 is assigned to Clonal Complex 17 (CC17) and is classified as DNA sequence type 78 based on multi-locus sequence typing of seven housekeeping genes. The complete genome sequence of *E. faecium*, strain U0317 is available (GenBank: [ABSW00000000](https://www.ncbi.nlm.nih.gov/nuclseq/ABSW00000000)).

*E. faecium* is a Gram-positive, facultative, anaerobic coccus that is a commensal inhabitant of the gastrointestinal tract of both humans and animals.<sup>1-3</sup> *E. faecium* is an emerging and challenging nosocomial pathogen due to its inherent hardiness and ability to develop antibiotic resistance.<sup>1,3</sup> Its large open pan-genome allows for horizontal gene transfer between *E. faecium* and other pathogenic and non-pathogenic bacteria to adapt to changing environments.<sup>1,4</sup> The large majority of strains isolated from nosocomial infections have been classified as CC17, with a distinct genetic lineage characterized by ampicillin resistance and a pathogenicity island carrying the *esp* gene, which is known to contribute virulence in an animal model.<sup>1,4,5</sup> Two other virulence genes, *hyl* and *acm*, have been identified.<sup>1</sup>

**Material Provided:**

Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

**Packaging/Storage:**

NR-28982 was packaged aseptically, in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term

storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

**Growth Conditions:**

Media:

Tryptic Soy broth or Brain Heart Infusion broth or equivalent  
Tryptic Soy agar or Tryptic Soy agar with 5% defibrinated sheep blood or Brain Heart Infusion agar or equivalent

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate tube, slant and/or plate for 1 day.

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Enterococcus faecium*, Strain U0317, NR-28982."

**Biosafety Level: 2**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmb15/index.htm](http://www.cdc.gov/biosafety/publications/bmb15/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for

damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. van Schaik, W., et al. "Pyrosequencing-Based Comparative Genome Analysis of the Nosocomial Pathogen *Enterococcus faecium* and Identification of a Large Transferable Pathogenicity Island." BMC Genomics 11 (2010): 239. PubMed: 20398277.
2. Schleifer, K. H. and R. Kilpper-Bälz. "Transfer of *Streptococcus faecalis* and *Streptococcus faecium* to the Genus *Enterococcus* nom. rev. as *Enterococcus faecalis* comb. nov. and *Enterococcus faecium* comb. nov." Int. J. Syst. Bacteriol. 34 (1984): 31-34.
3. Arias, C. A. and B. E. Murray. "The Rise of the *Enterococcus*: Beyond Vancomycin Resistance." Nat. Rev. Microbiol. 10 (2012): 266-278. PubMed: 22421879.
4. Heikens, E., et al. "Identification of a Novel Genomic Island Specific to Hospital-Acquired Clonal Complex 17 *Enterococcus faecium* Isolates." Appl. Environ. Microbiol. 74 (2008): 7094-7097. PubMed: 18836023.
5. Willems, R. J., et al. "Global Spread of Vancomycin-Resistant *Enterococcus faecium* from Distinct Nosocomial Genetic Complex." Emerg. Infect. Dis. 11 (2010): 821-828. PubMed: 15963275.
6. Maxson, T., et al. "Rapid Antibiotic Susceptibility Testing from Blood Culture Bottles with Species Agnostic Real-Time Polymerase Chain Reaction." PLoS One 13 (2018): e0209042. PubMed: 26611826.

ATCC® is a trademark of the American Type Culture Collection.

